Stock market today: S&P 500 ekes gain as hopes for end of shutdown get major boost
Executive Vice President and CLO of Ptc Therapeutics (NASDAQ:PTCT), Mark Elliott Boulding, sold a total of 3,375 shares of common stock on October 7, 2025, at prices ranging from $62.89 to $64.97, totaling approximately $214,091. The transaction comes as PTCT trades near its 52-week high of $67.40, with the stock delivering an impressive 65% return over the past year and reaching a market capitalization of $5.25 billion.
Boulding also exercised options to acquire 3,375 shares of Ptc Therapeutics common stock at a price of $38.10, for a total value of $128,587. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on December 5, 2024.
Following these transactions, Boulding directly owns 103,901 shares of Ptc Therapeutics.
In other recent news, PTC Therapeutics has been in the spotlight with several significant developments. The company received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for vatiquinone, a treatment for Friedreich’s ataxia, indicating that substantial evidence of efficacy was not demonstrated. This regulatory setback has led to differing analyst opinions. Goldman Sachs reiterated its Sell rating with a $44 price target, while Jefferies lowered its price target to $63 but maintained a Buy rating. Truist Securities also held its Buy rating, setting a price target of $86, viewing the CRL as a "clearing event" ahead of other upcoming regulatory updates. Meanwhile, BofA Securities has maintained its Buy rating and $76 price target, highlighting the potential of PTC Therapeutics’ Sephience drug for phenylketonuria following its recent approval. The company began shipping Sephience in August and plans to share early launch metrics in future earnings calls. These developments reflect a mixed outlook for PTC Therapeutics among analysts and investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.